Mandate Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2018

The board of directors of Xspray Pharma AB (publ) has resolved on a directed new issue of shares, whereby Xspray Pharma will raise proceeds of approximately SEK 92 million, before issue costs. 

Xspray Pharma is a product development company with several product candidates in clinical development. Xspray Pharma uses its patented RightSize technology to develop improved generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. 

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Edin Agic and Julia Hirschberg.

Summary of employment related news in Sweden as of January 2021

Short-time work, a new pandemic law and pending changes to the Employment Protection Act. Here is the latest employment related news in Sweden.
January 19, 2021

Sanctions round-up

Not so long ago, sanctions were a rare occurrence which only involved obscure products and countries, and which were decided by the members of the United Nations Security Council. Today, the European Union and particularly the United States, impose sanctions and other trade restrictions with high frequency which have the potential to affect any type of transaction. Set forth below is a summary of some recent developments.
December 22, 2020